Latest News
Untreated IPF Associated With 50% All-Cause Mortality, Study Finds
New Imaging Tracking System Could Clarify Stem Cell Role in IPF Therapy
Modifying Microbiome Could Prevent IPF Progression
TLR3 Mutations May Increase Risk of Death From Acute Exacerbations in IPF
New Findings Suggest Why Patients With IPF and Infection Have Higher Death Risk
Study Results Show Decreased Adverse Events in IPF With LYT-100
Low-Dose Pirfenidone Could Benefit Patients With IPF
Ongoing Antifibrotic Therapy Associated With Improved Outcomes in IPF
Pheretima Protein May Be Used to Treat IPF
Latest Clinical Trials
Features
New Venture Aims to Improve Diagnosis, Treatment of Pulmonary Fibrosis
Three Lakes Foundation, Yale University, and the University of Pittsburgh are joining forces to speed up the search for treatments for pulmonary fibrosis.
Israel Emerges as Global Powerhouse in Rare Disease Research
TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…
Dr. Noah Greenspan, Advocacy Groups: Avoiding COVID-19 Holds a Special Urgency for IPF Patients
Nearly 11 years ago, Dallas, Texas retiree Bill Vick was training for a triathlon and noticed that his swimming performance had started to decline. At the time, he was 72 and seemingly in peak health. “I went to the doctor, not because I felt bad, but because I was worried about my times and distances,…
Treating IPF Patients in the Age of COVID-19
NEW YORK, New York — Noah Greenspan, DPT, says the pulmonary fibrosis (PF) patients and others who had been coming to his Pulmonary Wellness and Rehabilitation Center until he closed it in March 2020 in the wake of the COVID-19 pandemic were among “the oldest, sickest, most complex patients in the book.” Since then, the…
NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…
IPF Clinical Insights
How Telomere Dysfunction Drives Pathogenesis in IPF
We explore how telomere dysfunction potentially drives the pathogenesis of idiopathic pulmonary fibrosis, and what that could mean for future research.
Understanding the Pathological Processes That Lead to Fibrosis in IPF
We explore the pathological processes that result in the fibrosis of the lungs in patients with idiopathic pulmonary fibrosis.
How a Medical Algorithm Could Improve Diagnosis of Acute Exacerbations of IPF
We explore a proposed medical algorithm for diagnosing acute exacerbations of IPF and discuss the use of medical algorithms in general.
The Potential Roles of Extracellular Vesicles in AATD and IPF
Extracellular vesicles (EVs) have been implicated in the pathogenesis of a variety of chronic respiratory diseases, including alpha-1 antitrypsin deficiency (AATD) and idiopathic pulmonary fibrosis (IPF). Their role in disease progression makes them an interesting target for diagnostic and therapeutic interventions. The multiple potential functions of EVs in these diseases are discussed by Purghè et…
Rare Care Podcast
Diagnosing and Treating IPF: Insights From Noah Greenspan, DPT, founder of New York City’s Pulmonary Wellness & Rehabilitation Center.
IPF Meeting Coverage
- Loading...
Loading...
Loading... 
Loading...